Corticosteroid-sparing strategies in the treatment of @entity4816 in XXXX .

@entity1 @entity32 @entity500 @entity1252 @entity262 @entity6383 @entity4816 @entity288
BACKGROUND: Systemic corticosteroids have been traditionally used in the therapy of @entity4816 in @entity1 with @entity1252 . The high morbidity associated with long-term corticosteroid therapy has prompted the use of corticosteroid-sparing strategies with cytotoxic agents. METHODS: This retrospective study summarizes the authors' experience of the last 10 years including 9 @entity1252 @entity1 with @entity4816 who required treatment for longer than 6 months. RESULTS: Seven of these @entity1 were treated with cytotoxic agents. Average follow-up was 39 months. @entity32 was controlled clinically and angiographically in all @entity1 using the following therapeutic regimens: systemic @entity288 and @entity6383 (n = 1 @entity1 ); systemic corticosteroids and cytotoxic chemotherapy (n = 6); cytotoxic chemotherapy and @entity6383 (n = 1); and @entity6383 alone (n = 1). Visual acuity was preserved (> 20/30) or improved in all @entity1 . All @entity1 retained excellent control of their @entity262 during their follow-up. Side effects of cytotoxic drugs requiring discontinuation of all chemotherapy were not encountered in this group; @entity500 therapy did result in substantial adverse effects necessitating its replacement with other drugs. CONCLUSION: These results suggest a valuable role for corticosteroid-sparing drugs in the therapy of @entity4816 associated with @entity1252 .
